Bristol Myers Squibb CN012-0068
About the Study
The purpose of this study is to assess the efficacy, safety, and tolerability of KarXT on voiding dynamics and urological safety in adults living with symptoms of schizophrenia.
Participants will be asked to pass urine into a funnel or special commode connected to a Flowstar Compact Digital Uroflowmeter. This device automatically measures urine flow and volume and provides a standard printout in real time. The device is FDA 510(k) cleared. Post-void Residual Volume Measurement (PVR) test measures the amount of urine left in the bladder after urination. Participants will lie in a supine position, a gel will be applied to the lower abdomen, and PVR will be measured using a portable bladder scanner.
This study is sponsored by Bristol Myers Squibb.
Eligibility
You may be eligible to participate in this study if you:
are between the ages of 18-65 years old
have a confirmed primary diagnosis of schizophrenia based on DSM-5 criteria
currently taking an antipsychotic at a stable therapeutic dose for at least 30 days prior to screening
are able to discontinue your current antipsychotic and initiate treatment with KarXT
If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.
If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.